|
OCR SC Clinical Trials
1 actively recruiting trial across 1 location
Also known as: Ocrevus Zunovo® USPI;, RO4964913
Birmingham, Alabama1 trial
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Alabama Neurology Associates
Phase 4
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.